• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    CooperCompanies to Participate in the William Blair Growth Stock Conference

    5/8/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care
    Get the next $COO alert in real time by email

    SAN RAMON, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today it will participate in the William Blair Growth Stock Conference on Thursday, June 5, 2025. Brian Andrews, Executive Vice President, Chief Financial Officer & Treasurer, will represent the Company in a session scheduled at 11:20 AM CT.

    The webcast will be available to investors and other interested parties by accessing the CooperCompanies' website at http://investor.coopercos.com.

    About CooperCompanies

    CooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 16,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.

    Contact:

    Kim Duncan

    Vice President, Investor Relations and Risk Management

    925-460-3663

    [email protected]



    Primary Logo

    Get the next $COO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $COO

    DatePrice TargetRatingAnalyst
    8/29/2024$115.00 → $120.00Overweight
    Piper Sandler
    7/16/2024$107.00 → $115.00Hold → Buy
    Jefferies
    3/19/2024$125.00Neutral → Buy
    Redburn Atlantic
    3/13/2024$100.00 → $120.00Neutral → Overweight
    JP Morgan
    2/6/2024Sector Weight
    KeyBanc Capital Markets
    10/30/2023$380.00Buy
    BofA Securities
    10/5/2023$390.00 → $343.00Overweight → Neutral
    Redburn Atlantic
    5/30/2023$410.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $COO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CooperCompanies to Participate in the William Blair Growth Stock Conference

      SAN RAMON, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today it will participate in the William Blair Growth Stock Conference on Thursday, June 5, 2025. Brian Andrews, Executive Vice President, Chief Financial Officer & Treasurer, will represent the Company in a session scheduled at 11:20 AM CT. The webcast will be available to investors and other interested parties by accessing the CooperCompanies' website at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two bu

      5/8/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies Appoints Barbara Carbone to Board of Directors

      SAN RAMON, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today that its Board of Directors has appointed Barbara Carbone as an independent director, effective May 1, 2025. Ms. Carbone has also been appointed to serve on the Audit Committee when she joins the Board. Ms. Carbone brings nearly four decades of experience across a wide variety of industries. She spent most of her career at KPMG LLP, from 1981-2019, where she served more than twenty-four years as an Audit Partner. She served on the KPMG Partnership Audit Committee for six years, including three years as the Chairperson, and as the National Partner in

      4/30/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies Announces Release Date for Second Quarter 2025

       SAN RAMON, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report second quarter 2025 financial results on Thursday, May 29, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 1515103. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful

      4/29/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care

    $COO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler reiterated coverage on Cooper with a new price target

      Piper Sandler reiterated coverage of Cooper with a rating of Overweight and set a new price target of $120.00 from $115.00 previously

      8/29/24 8:24:13 AM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Cooper upgraded by Jefferies with a new price target

      Jefferies upgraded Cooper from Hold to Buy and set a new price target of $115.00 from $107.00 previously

      7/16/24 7:26:08 AM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Cooper upgraded by Redburn Atlantic with a new price target

      Redburn Atlantic upgraded Cooper from Neutral to Buy and set a new price target of $125.00

      3/19/24 7:31:09 AM ET
      $COO
      Ophthalmic Goods
      Health Care

    $COO
    SEC Filings

    See more
    • The Cooper Companies Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

      8-K - COOPER COMPANIES, INC. (0000711404) (Filer)

      4/30/25 4:21:05 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • The Cooper Companies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - COOPER COMPANIES, INC. (0000711404) (Filer)

      4/2/25 5:11:06 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form 10-Q filed by The Cooper Companies Inc.

      10-Q - COOPER COMPANIES, INC. (0000711404) (Filer)

      3/7/25 4:22:17 PM ET
      $COO
      Ophthalmic Goods
      Health Care

    $COO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Carbone Barbara

      4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

      5/5/25 4:16:23 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form 3 filed by new insider Carbone Barbara

      3 - COOPER COMPANIES, INC. (0000711404) (Issuer)

      5/5/25 4:14:05 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Director Kozy William A converted options into 2,857 shares, increasing direct ownership by 10% to 31,149 units (SEC Form 4)

      4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

      4/3/25 4:09:38 PM ET
      $COO
      Ophthalmic Goods
      Health Care

    $COO
    Leadership Updates

    Live Leadership Updates

    See more
    • CooperCompanies Appoints Barbara Carbone to Board of Directors

      SAN RAMON, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today that its Board of Directors has appointed Barbara Carbone as an independent director, effective May 1, 2025. Ms. Carbone has also been appointed to serve on the Audit Committee when she joins the Board. Ms. Carbone brings nearly four decades of experience across a wide variety of industries. She spent most of her career at KPMG LLP, from 1981-2019, where she served more than twenty-four years as an Audit Partner. She served on the KPMG Partnership Audit Committee for six years, including three years as the Chairperson, and as the National Partner in

      4/30/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • Evolus Announces Appointment of Albert G. White III to Board of Directors

      Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes

      7/1/24 8:00:00 AM ET
      $COO
      $EOLS
      Ophthalmic Goods
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • CooperCompanies Appoints Lawrence E. Kurzius to Board of Directors

      SAN RAMON, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) announced today that its Board of Directors has appointed Lawrence E. Kurzius as an independent director, effective December 1, 2023. Kurzius has also been appointed to serve on the Audit Committee and Organization & Compensation Committee when he joins the Board. "We are thrilled to welcome Lawrence to our Board of Directors," said Al White, President and CEO. "His track record of successfully leading a complex, multinational organization will be extremely valuable to CooperCompanies as we continue to drive global growth at CooperVision and CooperSurgical." Kurzius served as Chief Executive Officer of McCo

      11/30/23 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care

    $COO
    Financials

    Live finance-specific insights

    See more
    • CooperCompanies Announces Release Date for Second Quarter 2025

       SAN RAMON, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report second quarter 2025 financial results on Thursday, May 29, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 1515103. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful

      4/29/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies Announces First Quarter 2025 Results

      SAN RAMON, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2025. Revenue increased 4% year-over-year to $964.7 million. CooperVision (CVI) revenue up 4% to $646.1 million, and CooperSurgical (CSI) revenue up 3% to $318.6 million.GAAP diluted earnings per share (EPS) of $0.52, up $0.11 from last year's first quarter.Non-GAAP diluted EPS of $0.92, up $0.07 from last year's first quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, Cooper's President and CEO said, "We started the y

      3/6/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • CooperCompanies Announces Release Date for First Quarter 2025

      SAN RAMON, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) today announced it will report first quarter 2025 financial results on Thursday, March 6, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 7466264. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business unit

      2/3/25 4:15:00 PM ET
      $COO
      Ophthalmic Goods
      Health Care

    $COO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

      SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

      2/16/24 4:57:01 PM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13G filed by The Cooper Companies Inc.

      SC 13G - COOPER COMPANIES, INC. (0000711404) (Subject)

      2/14/24 10:04:33 AM ET
      $COO
      Ophthalmic Goods
      Health Care
    • SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

      SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

      2/13/24 5:02:29 PM ET
      $COO
      Ophthalmic Goods
      Health Care